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Abstract
Introduction: The ataxia-telangiectasia mutated (ATM) gene (MIM ID 208900) encodes a protein kinase that plays a
significant role in the activation of cellular responses to DNA double-strand breaks through subsequent
phosphorylation of central players in the DNA damage-response pathway. Recent studies have confirmed that
some specific variants in the ATM gene are associated with increased breast cancer (BC) risk. However, the
magnitude of risk and the subset of variants that are pathogenic for breast cancer remain unresolved.
Methods: To investigate the role of ATM in BC susceptibility, we studied 76 rare sequence variants in the ATM
gene in a case-control family study of 2,570 cases of breast cancer and 1,448 controls. The variants were grouped
into three categories based on their likely pathogenicity, as determined by in silico analysis and analyzed by
conditional logistic regression. Likely pathogenic sequence variants were genotyped in 129 family members of 27
carrier probands (15 of which carried c.7271T > G), and modified segregation analysis was used to estimate the BC
penetrance associated with these rare ATM variants.
Results: In the case-control analysis, we observed an odds ratio of 2.55 and 95% confidence interval (CI, 0.54 to
12.0) for the most likely deleterious variants. In the family-based analyses, the maximum-likelihood estimate of the
increased risk associated with these variants was hazard ratio (HR) = 6.88 (95% CI, 2.33 to 20.3; P = 0.00008),
corresponding to a 60% cumulative risk of BC by age 80 years. Analysis of loss of heterozygosity (LOH) in 18 breast
tumors from women carrying likely pathogenic rare sequence variants revealed no consistent pattern of loss of the
ATM variant.
Conclusions: The risk estimates from this study suggest that women carrying the pathogenic variant, ATM c.7271T
> G, or truncating mutations demonstrate a significantly increased risk of breast cancer with a penetrance that
appears similar to that conferred by germline mutations in BRCA2.
Introduction
The ataxia-telangiectasia mutated (ATM) gene (MIM ID
208900) encodes a protein kinase that plays a major role
in activating cellular responses to DNA double-strand
breaks through downstream phosphorylation of central
players in the DNA damage-response pathways, includ-
ing BRCA1, p53, and Chk2 [1].
More than 20 years ago, Swift et al. [ 2 ]r e p o r t e dt h a t
female relatives of patients with the autosomal recessive
condition, ataxia-telangiectasia (AT), have an elevated
risk of cancer, particularly breast cancer. Since the clon-
ing of the ATM gene in 1995 [3], many case-control
studies have carried out mutation screening and single
nucleotide polymorphism (SNP) genotyping to clarify
t h er o l eo fATM genetic variation in breast cancer pre-
disposition [4-10]. Initially, most mutation-screening
studies were limited to protein-truncating mutations
identified by using the protein-truncating test [11], and
many of them were underpowered [12].
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sition remained controversial until Renwick et al. [13]
screened a series of “familial” breast cancer cases
selected for having a strong family history and controls
unselected for family history of breast cancer. Invoking
a multiplicative model in which risk modified a pre-
sumed underlying polygenic effect, they estimated that
the variants that are known to cause AT in the bi-alle-
lic state confer, on average, a moderately increased risk
of breast cancer of about 2.4-fold (95% confidence
interval (CI), 1.51 to 3.78) (see also [14]). However,
this study did not distinguish between the effects of
protein-truncating and missense mutations, although
Gatti et al. [15] had hypothesised in 1999 that, com-
pared with protein-truncating mutations, some mis-
sense variants in ATM might act as dominant
negatives and confer a particularly high risk of breast
cancer when heterozygous, although causing a milder
form of AT when homozygous.
To determine which rare missense variants in ATM
were likely to confer an increased risk of breast cancer,
and to compare this with the risk conferred by protein-
truncating mutations, we previously carried out a meta-
analysis of published data and also mutation screened
almost 1,000 breast cancer cases and a similar number of
controls [16]. In addition, that study classified the rare
missense variants by using an in silico missense substitu-
tion analysis that provides a ranking of missense variants
from evolutionarily most likely (C0) to least likely (C65).
We found marginal evidence that protein-truncating (T)
and splice-site junction (SJ) mutations confer on average
a moderately increased risk of breast cancer (odds ratio
(OR), 2.3; 95% CI, 1.1 to 4.8), but stronger evidence that
a subset of rare, evolutionarily unlikely missense (rMS)
C65 substitutions conferred on average a higher risk of
breast cancer (OR, 18; 95% CI, 3 to 120).
To define better the risks associated with these classes
of ATM variants, and to determine whether they were
likely to act as dominant negatives, we genotyped a
large panel of rare missense variants, as well as truncat-
ing and splice-junction mutations, in breast cancer cases
and controls from four large studies. We also genotyped
all available relatives of breast cancer cases found to
carry putative breast-cancer associated ATM variants to
estimate their penetrance. In addition, we carried out
loss of heterozygosity (LOH) analyses and a review of
the pathology of breast tumors from these mutation
carriers.
Materials and methods
Subjects
We studied Caucasian cases of breast cancer (n =2 , 5 1 7
invasive and 53 DCIS) and controls (n = 1,448) from
three sources: (a) population-based case and control
breast cancer families from the NCI-sponsored Breast
Cancer Family Registry (BCFR) [17]; (b) a clinic-based
resource of Australian and New Zealand multiple-case
breast cancer families from the Kathleen Cuningham
Foundation Consortium for Research on Familial Breast
Cancer (kConFab) [18]; and (c) Australian female con-
t r o l sc h o s e nf r o mt h eR e dC r o s sB l o o dB a n kt ob ee t h -
nically and frequency matched for age to the age at
diagnosis of kConFab cases [19] (Table 1). The kConFab
cases were those from whom DNA was available who
had the youngest age at diagnosis in the family. All sub-
jects in these studies provided informed consent for par-
ticipation in genetic and family studies. We excluded
any subjects who had previously been included in the
sequencing study of Tavtigian [16] but noted that some
of the included BCFR subjects overlap with those of
Bernstein et al. [10], although they genotyped only two
variants, one of which is in our iPLEX [10]. The indivi-
dual resource collections (BCFR, kConFab), as well as
the specific ATM study, have been approved by the rele-
vant ethical committees.
Selection of ATM variants and genotyping
Missense variants and in-frame deletions were assessed
for the degree of conservation within the ATM multiple
protein sequence alignment and for the predicted sever-
ity of the amino acid substitution, according to the
Align-GVGD class, as previously described [16,20]. We
selected all the A-GVGD class C55/C65 variants
reported previously [16], as well as a subset of the C0,
C15, C25, C35, and C45 variants (Additional file 1). In
addition, we included three variants identified in the lit-
erature [13,21] and 17 that we had found by sequencing
of familial breast cancer cases from the population-
based (Northern California, Ontario, Australia) and
clinic-based (Philadelphia, New York, Utah) sites of the
BCFR (unpublished data). The MassARRAY assay
design software (Version 3.1) was used to select oligo-
nucleotide sequences that were best suited for genotyp-
ing according to the guidelines of Sequenom Inc San
Diego, CA, USA. Sequences are available on request.
Primer extension reactions were carried out according
to the manufacturer’s instructions for iPLEX chemistry.
Genotypes were analyzed by using Sequenom TYPER
software (Version 3.1). Positive controls for 67 of the 79
variants were included in the iPLEX genotyping. All the
rare variants detected by iPLEX and a random selection
of the common variants (for QC purposes) were con-
firmed by direct sequencing by using newly designed
PCR primers. In addition, we applied similar QC criteria
to those used by the Breast Cancer Association Consor-
tium [22]. Forty-five samples failed QC, but only three
of 79 genotyped variants failed QC (ATMc.6067G > A;
ATMc.6820G > A;
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three groups: Group 1 consisted of 36 missense variants
with an A-GVGD class of C0 or C15. Group 2 consisted
of a total of 18 variants comprising intronic variants
(other than those at ± 1 or 2); variants in A-GVGD
classes C25, C35, C45; as well as variants in class C55
or C65 that fell outside the FAT and kinase domains of
the ATM protein. Group 3 consisted of 22 C55 and C65
variants in the FAT and kinase domains [16], as well as
protein-truncating variants (either splice, nonsense, or
frameshift).
Family genotyping and loss of heterozygosity analysis
To estimate the penetrance of the likely deleterious
ATM variants, 129 family members of women who had
been found to carry a truncating mutation (n =1 0 ) ,
splice-site variant (n = 1), or evolutionarily unlikely mis-
sense substitution (C65 and C55) in the FAT, kinase,
and FATC domains (n = 16) were genotyped for the
respective variant by direct sequencing (Table 2). In
eight of these families, no additional DNA samples were
available, but because they were from population-based
sources, they were informative for the penetrance esti-
mation. Twenty-four tumor blocks were available for
LOH analysis from 18 different affected cases and
female relatives carrying a putative breast-cancer asso-
ciated variant. Sections were cut, and one slide was
stained with hematoxylin and eosin (H&E) and reviewed
by a pathologist (LdS). If the section contained at least
70% tumor cells, then the slide from an adjacent
unstained section was macro-dissected and DNA iso-
lated [23]. For two cases in which fewer than 70%
tumor cells were present in the section, tumor cells
were collected by laser capture micro-dissection (LCM)
before DNA isolation [24]. Primers that spanned the
relevant region were then designed to generate a small
PCR product, and the tumor and germline DNA were
sequenced in tandem. LOH was scored by the absence
of the heterozygous peak seen in the germline sample.
Pathology review
A blinded pathology review was performed by one of us
(SRL) on 35 H&E slides of ATM-positive breast tumors
(from 21 different carriers of Group 3 ATM variants)
and H&E slides of 38 control breast tumors (age
matched within 6 years) ascertained from the Royal
Brisbane and Women’s Hospital between 2004 and
2009. The slides were scored for pathologic features by
using a modified pro forma that was initially developed
for studies on the pathology of BRCA-associated can-
cers. Specifically, we assessed for the presence of in situ
disease (LCIS and DCIS), invasive tumor type, and over-
all nuclear grade by using the modified Nottingham
Grading System [25], and for the presence of apocrine,
“basal” (pushing margins, central acellular or necrotic
zones, lymphocytic infiltrates) and squamous differentia-
tion. These features were assessed without ancillary
immunohistochemical methods.
Statistical methods
Conditional logistic regression was used to examine the
associations between variants in a given class and the risk
of breast cancer, stratified by study center, by using a case-
control design. To guard against results driven by individual
study centers, we also performed Mantel-Haenszel c
2 ana-
lysis comparing each variant group against the reference,
stratified by study center. All analyses were performed by
using STATA 10.0 (Statcorp, College Station, TX).
Penetrance of ATM variants was estimated by using
modified segregation analysis of family genotypes
adjusted for ascertainment. Models were fitted under
maximum likelihood theory by using the statistical pack-
age Mendel///version 3.2 [26]. Noncarriers were
assumed to be at population risks specific to Australia,
Canada, and the United States, with incidence rates
taken from cancer registry data obtained from Cancer
Incidence in Five Continents, VIII (IARC, Lyon), and
hazard ratios (HR, the age-specific breast cancer inci-
dence rate in carriers divided by the relevant population
rate) were estimated. Ascertainment was accounted for
by conditioning the likelihood of each family on the
proband’s genotype and phenotype (for population-
based families that were selected irrespective of family
history) or on all phenotypes and the proband’sg e n o -
type (for clinic- and population-based families that had
been selected because of a family history).
Table 1 Numbers of cases and controls by center, after exclusions
Center Number of cases (DCIS) Average age at diagnosis Number of controls Reference age
Australia BCFR 820 (4) 46 320 45
Ontario BCFR 1,141 (21) 50 591 51
Northern California BCFR 266 (8) 48 377 48
kConFab/RCBB 343 (20) 46 160 46
Total 2,570 (53) 47.9 1,448 48.4
Reference age is defined as age at diagnosis for cases and age at enrollment for controls.
BCFR, Breast Cancer Family Registry; DCIS, ductal carcinoma in situ; kConFab, Kathleen Cuningham Foundation Consortium for Research into Familial Breast
Cancer.
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used that incorporated the effect of an unmeasured
polygenic factor on breast cancer risk in addition to any
effect due to the ATM variant segregating in the pedi-
gree. P Values for the modified segregation analyses
were based on the likelihood ratio test and were two-
sided. Cumulative risk estimates were calculated from
the hazard-ratio estimates as 1 minus the exponential of
t h ec u m u l a t i v ei n c i d e n c e ,a n dt h ec o r r e s p o n d i n gc o n f i -
dence intervals were calculated by using a parametric
bootstrap with 5,000 replications. The model assumed a
dominant mode of action of the ATM variants on breast
cancer risks and a combined allele frequency of 0.001
for the variants in the population.
In separate analyses, we examined the risk associated
with these ATM variants compared with those asso-
ciated with BRCA2, as estimated by Antoniou et al.,
2003 [30]. In these analyses, the age-specific HR (by
decade) was assumed to be a constant multiple of the
Antoniou et al. estimate, with cumulative penetrances
re-estimated at each trial value of the multiplier. This
allowed a similar pattern of age-specific effects as in
BRCA2, but required estimation of only a single
parameter.
Results
Of the 76 ATM variants that passed QC, 29 were
observed one or more times in the analyzed set of 2,570
cases and 1,448 controls (Additional file ). Table 3
shows the distribution of variants and number of cases
and controls by group and the results of the logistic
regression. Overall, no significant association was found
between any variant group and the risk of breast cancer.
In particular, we observed an odds ratio of 2.55; 95% CI
(0.54 to 12.0) for the Group 3 variants, which included
the most likely deleterious missense variants and the
truncating variants. No evidence was apparent for any
heterogeneity in odds ratios between the four study cen-
ters. Inclusion of age into the model did not change the
results, nor did exclusion of 163 Ashkenazi Jewish
Table 2 Characteristics of the families used in the estimation of ATM penetrance
Family ID Variant Type Total BC BC < 50 ATM
+ (obligates) ATM
- No. of Individuals
O01
1 c.170G > A TSJ 3 2 1 0 21
O02
4 c.1924G > T TSJ 3 2 2 0 10
K01
1 c.3802delG TSJ 2 2 2 1 24
N01
4 c.3802delG TSJ 2 1 1 1 24
A01
5 c.3802delG TSJ 1 1 0 0 10
O03
5 c.3802delG TSJ 4 0 0 0 16
K02
1 c.5623C > T TSJ 6 2 3 11 159
N02
4 c.6997dupA TSJ 4 0 0 2 15
K03
1,2,3 c.7271T > G M 5 3 9 7 82
K04
5 c.7271T > G M 9 6 7 22 162
K05
1 c.7271T > G M 3 2 1 1 21
K06
1 c.7271T > G M 8 5 0 13 72
K07
1 c.7271T > G M 6 4 3 2 38
K08
5 c.7271T > G M 4 2 3 (3) 4 66
K09
1 c.7271T > G M 5 4 2 1 36
N03
2 c.7271T > G M 3 2 0 0 16
O04
5 c.7271T > G M 3 1 0 (1) 0 18
O05
2 c.7271T > G M 1 1 0 0 17
O06
5 c.7271T > G M 2 1 0 0 18
O07
2 c.7271T > G M 2 0 0 0 19
O08
5 c.7271T > G M 4 1 0 3 31
O09
2 c.7271T > G M 5 4 0 0 15
O10
2 c.7271T > G M 3 1 0 1 23
N04
4 c.7831_7835del TSJ 5 0 1 1 23
K10
1 c.7886_7890del TSJ 2 2 0 1 26
O11
5 c.8734A > G M 5 1 1 1 26
K11
1 c.8851-1G > T TSJ 8 1 7 14 154
Total 108 51 43 (4) 86 1142
M, missense variant; TSJ, truncating or splice-site mutation.
1 Tavtigian et al (2009);
2 Bernstein et al (2006);
3 Chenevix-Trench et al (2002);
4 found by direct sequencing (unpublished data);
5 found by iPLEX, this study.
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have harbored a founder mutation (results not shown).
Similarly, exclusion of the 53 DCIS cases had little effect
on the results. In addition, to account for individual
failed assays (after eliminati n gt h o s et h a th a df a i l e d1 6
or more assays), we estimated the probability that a
given individual belonged to each group based on the
number of failed assays composing that group.
Penetrance analysis in families
We genotyped additional relatives in all 27 families in
which putative pathogenic variants had been identified.
The specific variants included 16 missense variants, of
which 15 were p.Val2424Gly (c.7271T > G)
(rs28904921), seven were frameshifts (of which four
were c.3802delG), three were nonsense mutations, and
one was a consensus splice-site variant (all variants
included in the family analysis are indicated in Table 2).
In total, 129 additional DNA samples were available for
genotyping in relatives of the probands; 86 were nega-
tive for the family-specific variant (10 affected and 76
unaffected individuals), and 43 were positive (14 affected
and 29 unaffected individuals). In the analysis of the
ATM family data by using a mixed model (ATM gene
plus polygenic background), the presence of an ATM
variant increased breast cancer risk by an estimated fac-
tor of 6.88 (95% CI, 2.33 to 20.3; P = 0.00008) and did
not depend on age (P = 0.9). The estimated cumulative
risks of developing breast cancer for female carriers,
assuming US SEER incidence rates, are shown in Figure
1. Separate analyses of the 15 families carrying the ATM
c.7271T > G variant found that this variant increased
breast cancer risk by a factor of 8.0 (95% CI, 2.3 to 27.4;
P = 0.0005) compared with 4.4 (95% CI, 0.70 to 28.1; P
= 0.053) for families with other variants.
Under the assumption that the penetrance of the
ATM variants was a constant multiplier of the BRCA2
penetrance, the value of the multiplier that resulted in
t h eb e s tf i tt ot h ep e d i g r e ed a t aw a s0 . 7 5( 9 5 %C I ,0 . 3 3
to 1.50), indicating that the ATM alleles segregating in
these 27 families were associated with risks equivalent
to 75% those of BRCA2. In the 16 families with a mis-
sense variant, the penetrance estimate was 1.1 that of
BRCA2, whereas in the 11 families with a truncating or
splice junction (TSJ) mutation, the best estimate was
0.3, although this difference was not significant (c
2 =
2.99; P = 0.08).
Loss of heterozygosity analysis
LOH results for the 18 different affected women are
summarized in Table 4. Identical LOH results were
obtained for all six cases in which two different blocks
from the same tumor were tested. Four of the seven
cases with a truncating mutation in ATM showed loss
of the mutant allele, and the remainder showed no
LOH. Of the eight cases with the C65 variant, p.
Val2424Gly (ATMc.7271T > G), one showed loss of the
wild-type, one showed partial loss of the mutant, and
the remainder showed no LOH. Of the remaining two
cases with C55 or C65 variants, one showed loss of the
mutant allele, and the other had no LOH.
Pathology review
We compared the ATM-positive tumors with a set of
age-matched control breast tumors. No statistically sig-
nificant difference was noted in overall histologic grade.
Looking at the three individual components of grade
(tubule formation, nuclear pleomorphism, and mitotic
Table 3 Breast cancer risk associated with each group of ATM variants
Group Number of Variants Cases Controls Odds Ratio 95% confidence interval
No variant (referent) - 2,423 1,367 1.0
Group 1 19 79 45 0.99 0.67-1.45
Group 2 8 59 334 1.10 0.71-1.70
Group 3 3 9 2 2.55 0.54-12.0
Group 1 includes all rare variants classified by the A-GVGD algorithm as C0; Group 3 includes all rare variants that are C55/C65 in either the FAT or kinase
domains of the ATM protein as well as all truncating variants and splice variants at the consensus sites. Group 2 includes all other rare variants (see Additional
file 1 for details). ATM, Ataxia telangiectasia mutated.
Figure 1 Penetrance of the ATM variants associated with
breast cancer risk. Solid line, Maximum likelihood estimate of
cumulative risk of breast cancer; dashed lines, lower and upper 95%
confidence limits.
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morphism or tubule scores. However, a marginally sig-
nificant association was seen between the mitotic score
(exact P = 0.049), largely because of the paucity of ATM
tumors with a mitotic score of 3 (two of 18 compared
with 14 of 34 of the control tumors). This was also sup-
ported by analysis of the quantitative count of mitoses
per 10 high-power fields, with some suggestion of lower
mitotic rates in the ATM tumors than in the control
tumors (7.9 versus 19.0 mitoses per 10 high-power
fields; P =0 . 0 2b yt test, with Welch correction for
unequal variances).
Discussion
Gatti et al. [15] hypothesised in 1999 that, compared
with protein-truncating mutations, some missense
variants in ATM might act as dominant negatives and
confer a particularly high risk of breast cancer when
heterozygous, while causing a milder form of AT, when
homozygous. It was later shown that a missense muta-
tion, ATM c.7271T > G (p.Val2424Gly), appears to con-
fer a high risk of breast cancer and to act as a dominant
negative [31,32]. This mutation was first identified in a
Scottish family with a mild form of AT [33] and subse-
quently found in an Australian family [31], but initial
estimates of the magnitude of risk were imprecise.
Screening of nearly 4,000 population-based breast can-
cer cases for this mutation identified another six carrier
families, and, based on their breast cancer family his-
tories, risk for this mutation was estimated to be
increased by ninefold (95% CI, 4 to 19) [10].
To refine the risks associated with different classes of
ATM variants, and to examine the molecular pathologic
characteristics of ATM-positive tumors, we genotyped
76 rare ATM variants in 2,570 breast cancer cases and
1,448 controls. In addition, we genotyped specific var-
iants in the relatives of probands carrying ATM variants
judged likely to be pathogenic. Because, by definition,
we expect variants conferring moderate to high risks of
breast cancer to be rare in the general population, tradi-
tional case-control studies of even several thousand
cases and controls are typically underpowered to detect
associations with these sequence variants. We could
potentially pool these variants and compare the aggre-
gate frequency of these variants to increase power. How-
ever, the power is often reduced because of the inherent
heterogeneity of such variants, in which only a minority
is associated with increased risk. One strategy to address
this problem is to use in silico methods to group var-
iants into categories based on their probability of repre-
senting variants that are damaging to the normal
protein function. Although a number of such methods
are available, we used the Align-GVGD that has been
applied to a number of genes, including BRCA1,
BRCA2, CHEK2, ATM, and mismatch-repair genes
[20,34]. However, even with this stratification, we still
had insufficient power to detect an association with
breast cancer with even the most likely pathogenic var-
iants (OR, 2.55 (95% CI, 0.54 to 12.0), although the
effect sizes were comparable with those previously
reported [16].
As in other studies of ATM a n db r e a s tc a n c e rr i s k
[13,16], the most common pathogenic variant in our
study was the ATM c.7271T > G (p.Val2424Gly). Ren-
wick et al. [13] did not compare the breast cancer risks
associated with protein-truncating versus missense
mutations in ATM.B e r n s t e i net al. [10] had previously
identified seven carriers of this mutation in the three
population-based sites of the BCFR; however, no family
members were genotyped in this study. In our study of
Table 4 Loss of heterozygosity in breast tumors from
carriers of putative breast cancer-associated ATM
variants
Nucleotide change Effect Site Identifier LOH
c.170G > A Protein
truncating
Ontario 43115 No LOH
c.442_446 delGACAT Protein
truncating
kConFab 62558 LOH of
variant
c.1924G > T Protein
truncating
Ontario 91015 No LOH
c.3802delG Protein
truncating
kConFab 81253 LOH of
variant
c.3802delG Protein
truncating
Ontario 43147 No LOH
c.5623C > T Protein
truncating
kConFab 31015 LOH of
variant
c.7271T > G Align GVGD
C65
kConFab 40012 No LOH
c.7271T > G Align GVGD
C65
kConFab 40032 LOH of wild
type
c.7271T > G Align GVGD
C65
kConFab 40034 No LOH
c.7271T > G Align GVGD
C65
kConFab 70246 No LOH
c.7271T > G Align GVGD
C65
kConFab 60567 No LOH
c.7271T > G Align GVGD
C65
kConFab 20723 No LOH
c.7271T > G Align GVGD
C65
kConFab 51297 50% LOH of
variant
c.7271T > G Align GVGD
C65
kConFab 00574 No LOH
c.7638_7646del9 Align GVGD
C65
Ontario 91494 No LOH
c.7886_7890delTATTA Protein
truncating
kConFab 31277 LOH of
variant
c.8734A > G Align GVGD
C65
Ontario 62131 LOH of
variant
ATM, ataxia telangiectasia mutated; kConFab, Kathleen Cuningham Foundation
Consortium for Research into Familial Breast Cancer; LOH, loss of
heterozygosity.
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tified the same four mutation carriers from the Ontario
BCFR site, as well as the one carrier from the Australian
BCFR site. We did not identify the two ATM c.7271T >
G (p.Val2424Gly) mutation carriers from the Northern
California BCFR site that Bernstein et al. [10] had iden-
tified because one was subsequently found also to carry
ap a t h o g e n i cBRCA2 mutation (and was thus excluded
from our study), and for the other, no DNA sample was
available for our analyses. This missense ATM variant
was first reported to be associated with a mild form of
AT and might have originated in the Orkney Islands in
Scotland and then spread throughout populations with
large numbers of Scottish immigrant populations, such
as those of Australia. Our analysis of independent sam-
ples from four case-control studies provided some sup-
port of the observation by Tavtigian et al. [31,32] that
this mutation (and perhaps other similar missense muta-
tions with dominant-negative activity) confers a higher
risk of breast cancer than do protein-truncating
mutations.
As a second approach to verifying and characterizing
t h er o l eo fATM sequence variants in breast cancer, we
took advantage of the fact that the resources from
which the cases were drawn had also included the rela-
tives of those cases, providing us with the ability to gen-
otype both affected and unaffected relatives of cases in
which potentially pathogenic variants had been identi-
fied. As in Bernstein et al. [ 1 0 ] ,e v e ni nc a s e si nw h i c h
no additional samples were available, the fact that the
some of the breast cancer cases analyzed were from the
population-based sites of the BCFR allowed us to make
inferences based on the observed incidence of cancer in
relatives of index cases carrying the specific ATM var-
iant. Our analyses of family data in 27 families of car-
riers of either protein-truncating (n = 11) or rare,
evolutionarily unlikely, potentially damaging missense
mutations (n = 16) demonstrated a significantly
increased risk of breast cancer with a penetrance that
appears similar to that conferred by germline mutations
in BRCA2.H o w e v e r ,e v e ni nas t u d yo ft h i ss i z e ,t h e
confidence intervals are wide. Suggestive evidence also
was noted from the family-based analysis that a higher
risk was associated with the ATM c.7271T > G (p.
Val2424Gly) mutation than with truncating mutations,
although these differences were not statistically signifi-
cant because of the relatively small sample size of
families. The penetrance associated with truncating
mutations was only marginally significant. If our esti-
mates of breast cancer risk are correct, then women car-
rying the ATM c.7271T > G variant would be at
sufficiently high risk to warrant screening for at least
this variant in multiple-case families without mutations
in BRCA1 or BRCA2. If such a variant is identified,
these women could be counseled in a manner similar to
that with BRCA2 carriers, and those affected with breast
cancer might also be candidates for treatment with
PARP inhibitors in a manner similar to that with
BRCA1 and BRCA2 carriers. This suggestion is based on
the evidence that the inhibition of PARP1 is syntheti-
cally lethal with mutation or loss of ATM, and the effect
is mediated through mitotic catastrophe independent of
apoptosis [35,36].
Consistent with the dominant-negative hypothesis
[15,31,32], we did not observe consistent loss of the
wild-type allele in tumors from carriers of missense var-
iants. Loss of both the wild-type and the variant allele
was observed in different tumors, whereas some tumors
from missense carriers exhibited no loss of either allele.
Interestingly, we noted that all four carriers of truncat-
ing mutations, in which LOH was present, showed loss
of the variant, rather than of the wild type, as would be
expected for a tumor-suppressor gene. This apparent
bias in allelic loss requires further investigation in larger
studies.
Blinded pathology review of 35 tumors from cases
who carried a likely deleterious ATM variant and a hos-
pital-based series of 38 age-matched control breast
tumors did not reveal any distinctive pattern of histo-
pathologic characteristics, as had been previously
reported in BRCA1 tumors [37]. However, some evi-
dence suggested that ATM tumors were associated with
a lower mitotic index than were control tumors, which
is in contrast to the clear increase in mitotic index asso-
ciated with BRCA1 tumors [37]. In agreement with this,
our previous expression analysis of six tumors from
ATM c.7271T > G mutation carriers showed that they
were all luminal A or B tumors, and we would not have
expected them to share histopathologic characteristics
with BRCA1 tumors [32]. In contrast to the evidence of
Dork et al. [12], who reported an increased frequency of
lobular breast cancers in ATM carriers, we did not
observe this in our series, with half the lobular or mixed
lobular/ductal in each group (P = 0.66).
Conclusions
This is the largest study to date investigating large num-
bers of rare missense variants in the ATM gene for asso-
ciation with breast cancer risk. In addition to the
standard case-control approach, we used the power of a
family-based design inherent in the two resources from
which the cases and controls were derived (BCFR and
kConFab) to estimate more precisely the risks of breast
cancer through genotyping of relatives of the probands
carrying the putative pathogenic variants. Although
Bernstein et al. [10] used a similar approach and five
probands overlapped between the two studies; it should
be noted that, unlike our study, Bernstein et al. did not
Goldgar et al. Breast Cancer Research 2011, 13:R73
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families in their analysis. Taken as a whole, our study
a d d st ot h eg r o w i n gb o d yo fe v i d e n c et h a tas u b s e to f
rare ATM variants confers levels of risk that may have
clinical implications for the women who carry them, as
well as for their at-risk family members.
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